Article thumbnail

Chiral Metallohelical Complexes Enantioselectively Target Amyloid β for Treating Alzheimer's Disease

By Meng Li, Suzanne E. Howson, Kai Dong, Nan Gao, Jinsong Ren, Peter Scott and Xiaogang Qu

Abstract

Stereochemistry is a very important issue for the pharmaceutical industry and can determine drug efficacy. The design and synthesis of small molecules, especially chiral molecules, which selectively target and inhibit amyloid-beta (A beta) aggregation, represent valid therapeutic strategies for treatment of Alzheimer's disease (AD). Herein we report that two triple-helical dinuclear metallosupramolecular complexes can act as a novel class of chiral amyloid-beta inhibitors. Through targeting alpha/beta-discordant stretches at the early steps of aggregation, these metal complexes can enantioselectively inhibit A beta aggregation, which is demonstrated using fluorescent living cell-based screening and multiple biophysical and biochemical approaches. To the best of our knowledge, this is the first report of enantioselective inhibition of A beta aggregation. Intriguingly, as a promising candidate for A

Topics: CALCIUM-CHANNELS, IN-VIVO, PEPTIDE, AGGREGATION, INHIBITION, TOXICITY, BINDING, COPPER, OLIGOMERS, METAL
Year: 2014
OAI identifier: oai:ir.ciac.jl.cn:322003/50632
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://ir.ciac.jl.cn/handle/32... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.